Going Green Early Tuesday, Low Float (NYSE American: MAIA) Has Multiple Triggered Technicals

MAIA Biotechnology, Inc. (NYSE American: MAIA) is all over our watchlist

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Going Green Early Tuesday, Low Float (NYSE American: MAIA) Has Multiple Triggered Technicals  *Click Here To Get Our Alerts Faster Via SMS* January 27th Dear Reader, MAIA Biotechnology, Inc. (NYSE American: MAIA) is all over our watchlist this morning following an early green surge. One major reason why? Several technical indicators are appearing bullish at the moment. In fact, Barchart is reporting at least 8 technical indicators to be triggered across the short, medium, and long term as of the opening bell this morning. Furthermore, the Barchart "Trend Seeker" composite indicator is also flashing early Tuesday. Another reason? MAIA has at least two separate analyst targets (more info below) pointing to potential triple-digit upside from current chart levels. Now, mix in a relatively low float of fewer than 33Mn shares highlighting the potential for heightened volatility on a daily basis. Spend a second to read my initial report below and consider (NYSE American: MAIA) for your watchlist. ----- A forward-looking biotech company is quietly reshaping how we think about next-generation therapeutics. By merging cutting-edge science with a disciplined development framework, they’re tackling complex illnesses with a focus on precision and patient outcomes. The team combines deep domain expertise with agile operations, enabling rapid translation from concept to candidate. Their work sits at the intersection of biology, technology, and data, aiming to unlock new pathways and expand what’s possible in medicine. If you’re curious about breakthrough science and the behind-the-scenes effort that turns ideas into potential treatments, this group warrants a closer look. Plus, back in 2024, when I brought this profile to your attention, it exploded approx. 275% within months. And with a low float, and two strong analyst targets pointing to triple-digit potential upside, this little-known NYSE American profile is topping our watchlist Tuesday: *MAIA Biotechnology, Inc. (NYSE American: MAIA)* And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out: #1. One Analyst's Target Suggests Over 400% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. #3. Another Analyst Target Suggests Over 275% Potential Upside From Monday's Close. #4. The Company Targets Key 2026 Clinical Milestones (High Probability Of Technical Success In Pivotal Phase 3 Trial). #5. Could Serious Momentum Be Building For This Under-The-Radar NYSE American Profile? But more on those in a second... MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase. A New Therapeutic Strategy THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020). Clinical Development THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. Second-Generation Telomere Targeting Agents MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. MAIA's Pipeline The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: Grab Sources And More Here: Company Website. Company Presentation. ----- As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out: #1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 400% Potential Upside From MAIA's Current Chart Levels. In November, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA. From Monday's closing valuation, that provides MAIA with upside potential over 400%! Check out some key report highlights: Conclusion. The start of Phase 3 is an important milestone toward FDA approval. If the study replicates the recent data from the Phase 2 trial, ateganosine could become significant new therapy for third-line NSCLC. We believe this would also provide significant proof-of-concept to support earlier use. We are reiterating our Outperform rating and $14 price target. ----- #2. MAIA Potential Catalyst - Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. According to info from the Yahoo Finance website, MAIA has a relatively low float. The website reports this profile to have roughly 32.15Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news pops up towards the beginning of 2026, could it provide a breakout spark when paired with this volatility potential? ----- #3. MAIA Potential Catalyst - Another Analyst Target Suggests Over 275% Potential Upside From Monday's Close. Last week, an analyst at Diamond Equity Research provided an update note on their (NYSE: MAIA) coverage. In the update, they retagged MAIA with a target of $10.27. From Monday's close, that target provides MAIA with a potential upside of over 275%. Here's some highlights from the report: With continued positive readouts, the initiation of THIO-104 (Phase 3 study) remains a key potential valuation catalyst, marking progression towards controlled clinical validation and potential registration. We have revised our valuation model to reflect the recent Q3 financial results, updated share count, and reassessed comparable company analysis, reiterating our valuation of $10.27 per share contingent on successful execution by the company. ----- #4. MAIA Potential Catalyst - The Company Targets Key 2026 Clinical Milestones (High Probability Of Technical Success In Pivotal Phase 3 Trial). MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine in NSCLC advances concurrent Phase 2 expansion and Phase 3 trials along strategic regulatory pathways Strong momentum toward goal of early commercial approval Potential breakthrough therapeutic for estimated $50+Bn global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update on 2025 achievements and highlighted key targeted milestones and growth catalysts for 2026. “MAIA’s strong clinical execution in 2025 delivered exceptional efficacy data for ateganosine sequenced with a checkpoint inhibitor, including disease control, response rates, and survival data well above standard of care benchmarks,” said MAIA founder and CEO Vlad Vitoc, M.D. “The results clearly differentiate our novel telomere-targeting science and support the U.S. FDA’s Fast Track designation granted in 2025, positioning ateganosine for potential eligibility under the Accelerated Approval and Priority Review regulatory pathways. Our statistical assessments of ateganosine imply a high probability of technical success in our concurrent Phase 3 and Phase 2 trials. As our first-in-class small molecule advances toward potential early commercial approval—possibly within 18 to 24 months—we believe our strong execution is driving a clear value-creation inflection point, with meaningful long-term benefits for stockholders.” ... Targeted 2026 Milestones Initial measures of efficacy from Phase 3 study. Interim disease control rates (DCR), overall response rates (ORR) and progression free survival (PFS) analysis of ateganosine compared to the control arm will support regulatory discussions. Strong interim data could lead to early full commercial approval. Conclusion of Part C of Phase 2 study. Expansion of the trial provides additional clinical efficacy data to support regulatory review for commercial approval. Engage in regulatory interactions with the FDA. Expand ongoing FDA dialogue under the Fast Track designation, including discussions around trial enhancements and prospects for Accelerated Approval and Priority Review. Clinical development of second-generation molecules to start in Phase 1 trials. Additional small molecules fully developed in-house with better expected efficacy compared to ateganosine. Read the full article here. ----- #5. MAIA Potential Catalyst - Could Serious Momentum Be Building For This Under-The-Radar NYSE American Profile? MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), appears to be gaining increasing attention in the oncology community as emerging clinical results continue to surpass expectations in advanced non-small cell lung cancer (NSCLC). With the therapy’s Phase 2 trial ongoing and a pivotal Phase 3 program initiated this week, ateganosine is being closely watched as one of the most distinctive investigational approaches in solid-tumor treatment today. We believe that MAIA has positioned itself at the forefront of a new scientific category in oncology. To our knowledge, Ateganosine remains the only direct telomere-targeting anticancer agent currently in clinical development anywhere—a key distinction in a treatment landscape where most therapeutic advances build upon established mechanisms rather than introduce entirely new ones. According to management, statistical assessments of the Phase 3 trial points to a very high probability of technical success for regulatory approval of ateganosine. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of NSCLC. ... Read the full article here. ----- MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts #1. One Analyst's Target Suggests Over 400% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. #3. Another Analyst Target Suggests Over 275% Potential Upside From Monday's Close. #4. The Company Targets Key 2026 Clinical Milestones (High Probability Of Technical Success In Pivotal Phase 3 Trial). #5. Could Serious Momentum Be Building For This Under-The-Radar NYSE American Profile? ----- We're kicking-off coverage on MAIA Biotechnology, Inc. (NYSE American: MAIA). As soon as updates are available, we'll get them out to you quickly. Stay tuned. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 01/27/2026 and ending on 01/27/2026 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred seventy one thousand two hundred fifty USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/maia-tek12/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice